Hexylresorcinol | CAS#136-77-6 | Antiseptic

Hexylresorcinol
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 591219

CAS#: 136-77-6

Description: Hexylresorcinol is a substituted dihydroxybenzene used topically as an antiseptic for the treatment of minor skin infections. It also increases new bone formation by supression of Kappa B signaling pathway.

Chemical Structure

Hexylresorcinol

CAS# 136-77-6

Instruction

Theoretical Analysis

MedKoo Cat#: 591219
Name: Hexylresorcinol
CAS#: 136-77-6
Chemical Formula: C12H18O2
Exact Mass: 194.13
Molecular Weight: 194.270
Elemental Analysis: C, 74.19; H, 9.34; O, 16.47

Price and Availability

Size	Price	Availability	Quantity
25g	USD 350	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: Hexylresorcinol; Ascaricid; Ascarinol; Ascaryl; NSC 1570; NSC-1570; NSC1570

IUPAC/Chemical Name: 4-Hexylresorcinol

InChi Key: WFJIVOKAWHGMBH-UHFFFAOYSA-N

InChi Code: InChI=1S/C12H18O2/c1-2-3-4-5-6-10-7-8-11(13)9-12(10)14/h7-9,13-14H,2-6H2,1H3

SMILES Code: OC1=CC=C(CCCCCC)C(O)=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 194.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Song JY, Kim SG, Park NR, Choi JY. Porcine Bone Incorporated With 4-Hexylresorcinol Increases New Bone Formation by Suppression of the Nuclear Factor Kappa B Signaling Pathway. J Craniofac Surg. 2018 Mar 20. doi: 10.1097/SCS.0000000000004517. [Epub ahead of print] PubMed PMID: 29561490.

2: Seok H, Kim MK, Kim SG. Reconstruction of partial maxillectomy defect with a buccal fat pad flap and application of 4-hexylresorcinol: a case report. J Korean Assoc Oral Maxillofac Surg. 2016 Dec;42(6):370-374. doi: 10.5125/jkaoms.2016.42.6.370. Epub 2016 Dec 27. PubMed PMID: 28053908; PubMed Central PMCID: PMC5206243.

3: Farris P, Zeichner J, Berson D. Efficacy and Tolerability of a Skin Brightening/Anti-Aging Cosmeceutical Containing Retinol 0.5%, Niacinamide, Hexylresorcinol, and Resveratrol. J Drugs Dermatol. 2016 Jul 1;15(7):863-8. PubMed PMID: 27391637.

4: Ahn J, Kim SG, Kim MK, Kim DW, Lee JH, Seok H, Choi JY. Topical delivery of 4-hexylresorcinol promotes wound healing via tumor necrosis factor-α suppression. Burns. 2016 Nov;42(7):1534-1541. doi: 10.1016/j.burns.2016.04.016. Epub 2016 May 16. PubMed PMID: 27198070.

5: Kweon H, Kim SG, Choi JY. Inhibition of foreign body giant cell formation by 4- hexylresorcinol through suppression of diacylglycerol kinase delta gene expression. Biomaterials. 2014 Oct;35(30):8576-84. doi: 10.1016/j.biomaterials.2014.06.050. Epub 2014 Jul 11. PubMed PMID: 25023393.

6: Makino ET, Mehta RC, Banga A, Jain P, Sigler ML, Sonti S. Evaluation of a hydroquinone-free skin brightening product using in vitro inhibition of melanogenesis and clinical reduction of ultraviolet-induced hyperpigmentation. J Drugs Dermatol. 2013 Mar;12(3):s16-20. PubMed PMID: 23545928.

7: Taylor JA, Mitchenall LA, Rejzek M, Field RA, Maxwell A. Application of a novel microtitre plate-based assay for the discovery of new inhibitors of DNA gyrase and DNA topoisomerase VI. PLoS One. 2013;8(2):e58010. doi: 10.1371/journal.pone.0058010. Epub 2013 Feb 26. PubMed PMID: 23469129; PubMed Central PMCID: PMC3582512.

8: Kim SG, Choi JY. 4-hexylresorcinol exerts antitumor effects via suppression of calcium oscillation and its antitumor effects are inhibited by calcium channel blockers. Oncol Rep. 2013 May;29(5):1835-40. doi: 10.3892/or.2013.2292. Epub 2013 Feb 19. PubMed PMID: 23427012.

9: Lee SW, Kim SG, Park YW, Kweon H, Kim JY, Rotaru H. Cisplatin and 4-hexylresorcinol synergise to decrease metastasis and increase survival rate in an oral mucosal melanoma xenograft model: a preliminary study. Tumour Biol. 2013 Jun;34(3):1595-603. doi: 10.1007/s13277-013-0690-6. Epub 2013 Feb 15. PubMed PMID: 23412976.

10: Kim SG, Kim AS, Jeong JH, Choi JY, Kweon H. 4-hexylresorcinol stimulates the differentiation of SCC-9 cells through the suppression of E2F2, E2F3 and Sp3 expression and the promotion of Sp1 expression. Oncol Rep. 2012 Aug;28(2):677-81. doi: 10.3892/or.2012.1845. Epub 2012 Jun 1. PubMed PMID: 22664654.

11: Kim SG, Lee SW, Park YW, Jeong JH, Choi JY. 4-hexylresorcinol inhibits NF-κB phosphorylation and has a synergistic effect with cisplatin in KB cells. Oncol Rep. 2011 Dec;26(6):1527-32. doi: 10.3892/or.2011.1436. Epub 2011 Aug 24. PubMed PMID: 21874263.

12: Kim SG, Hahn BD, Park DS, Lee YC, Choi EJ, Chae WS, Baek DH, Choi JY. Aerosol deposition of hydroxyapatite and 4-hexylresorcinol coatings on titanium alloys for dental implants. J Oral Maxillofac Surg. 2011 Nov;69(11):e354-63. doi: 10.1016/j.joms.2011.06.002. Epub 2011 Aug 6. PubMed PMID: 21821331.

13: Kim SG, Jeong JH, Park YW, Song JY, Kim AS, Choi JY, Chae WS. 4-Hexylresorcinol inhibits transglutaminase-2 activity and has synergistic effects along with cisplatin in KB cells. Oncol Rep. 2011 Jun;25(6):1597-602. doi: 10.3892/or.2011.1218. Epub 2011 Mar 17. PubMed PMID: 21424127.

14: Yen GC, Duh PD, Lin CW. Effects of resveratrol and 4-hexylresorcinol on hydrogen peroxide-induced oxidative DNA damage in human lymphocytes. Free Radic Res. 2003 May;37(5):509-14. PubMed PMID: 12797471.

15: Jiménez M, Escribano-Cebrián J, García-Carmona F. Oxidation of the flavonol fisetin by polyphenol oxidase. Biochim Biophys Acta. 1998 Nov 27;1425(3):534-42. PubMed PMID: 9838217.

16: Guandalini E, Ioppolo A, Mantovani A, Stacchini P, Giovannini C. 4-Hexylresorcinol as inhibitor of shrimp melanosis: efficacy and residues studies; evaluation of possible toxic effect in a human intestinal in vitro model (Caco-2); preliminary safety assessment. Food Addit Contam. 1998 Feb-Mar;15(2):171-80. PubMed PMID: 9602923.

17: Salsburg D. Does everything "cause" cancer: an alternative interpretation of the "carcinogenesis" bioassay. Fundam Appl Toxicol. 1989 Oct;13(3):351-8. Review. PubMed PMID: 2693170.

18: Dieter MP, Jameson CW, French JE, Gangjee S, Stefanski SA, Chhabra RS, Chan PC. Development and validation of a cellular transplant model for leukemia in Fischer rats: a short-term assay for potential anti-leukemic chemicals. Leuk Res. 1989;13(9):841-9. PubMed PMID: 2796389.

19: Chhabra RS, Huff JE, Haseman J, Hall A, Baskin G, Cowan M. Inhibition of some spontaneous tumors by 4-hexylresorcinol in F344/N rats and B6C3F1 mice. Fundam Appl Toxicol. 1988 Nov;11(4):685-90. PubMed PMID: 3229592.

20: National Toxicology Program . NTP Toxicology and Carcinogenesis Studies of 4-Hexylresorcinol (CAS No. 136-77-6) in F344/N Rats and B6C3F1 Mice (Gavage Studies). Natl Toxicol Program Tech Rep Ser. 1988 May;330:1-166. PubMed PMID: 12732906.

Your view history

Hexylresorcinol featured